导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.34% | 2500/4773 |
| 近一周 | -2.05% | 3314/5465 |
| 近一月 | -4.56% | 3319/5421 |
| 近一季 | -6.37% | 2383/5231 |
| 近半年 | -2.15% | 2030/4920 |
| 近一年 | 4.04% | 1939/4394 |
| 近两年 | 50.03% | 1497/2954 |
| 近三年 | 33.89% | 947/2253 |
| 成立以来 | 127.15% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.99% 2986/4961 |
13.27% 2036/5312 |
- - |
- - |
| 2025 | 23.39% 1874/4813 |
0.50% 1829/3635 |
1.17% 2437/4076 |
20.54% 1963/4524 |
0.68% 1845/4813 |
| 2024 | 17.14% 725/3463 |
3.14% 619/2808 |
-0.63% 804/3014 |
17.23% 1231/3129 |
-2.50% 2110/3463 |
| 2023 | -9.42% 1160/2656 |
4.44% 949/2280 |
-4.20% 1089/2385 |
-3.14% 854/2515 |
-6.54% 1822/2655 |
| 2022 | -19.43% 848/2207 |
-13.56% 784/1919 |
6.74% 617/2016 |
-14.02% 1013/2113 |
1.56% 1221/2208 |
| 2021 | -4.90% 964/1822 |
-1.68% 529/1255 |
1.99% 1024/1330 |
-6.20% 905/1466 |
1.11% 1004/1822 |
| 2020 | 37.77% 373/1250 |
-9.88% 726/1028 |
12.49% 684/1067 |
16.78% 135/1164 |
16.38% 176/1184 |
| 2019 | 42.13% 222/1092 |
24.62% 499/754 |
3.21% 57/804 |
4.08% 220/850 |
6.18% 645/918 |
| 2018 | -17.94% 136/834 |
- - |
- - |
- - |
-11.76% 347/691 |
| 2017 | 34.15% 41/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.64% 118/605 |
- - |
- - |
- - |
- - |
| 2015 | 0.68% 250/575 |
- - |
- - |
- - |
- - |
| 2014 | 51.54% 72/237 |
- - |
- - |
- - |
- - |
| 2013 | -10.63% 159/186 |
- - |
- - |
- - |
- - |
| 2012 | 11.24% 35/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.70% 34/102 |
- - |
- - |
- - |
- - |
| 2010 | -17.79% 45/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 中银中证A100指数增强 VS. 长安沪深300非周期A(740101) |